XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Fatty Acids
 Infectious Diseases
 Respiratory Medicine
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Nov 17th, 2006 - 22:35:04

Antibiotics Channel
subscribe to Antibiotics newsletter

Latest Research : Pharmacology : Antibiotics

   DISCUSS   |   EMAIL   |   PRINT
Peptide Deformylase Inhibitors : A Novel Class of Antibiotics for Resistant Bacteria
Mar 5, 2005, 06:50, Reviewed by: Dr.

"With the preclinical studies started and an aggressive development timeline established, we expect this candidate to move from preclinical studies into the clinic in a timely manner."

Vicuron Pharmaceuticals Inc. announced today that the company has received another milestone payment from Novartis Pharma AG in recognition of follow-up lead product candidates identified for Novartis' development from its ongoing research collaboration focused on peptide deformylase inhibitors, a novel class of antibiotics.

The company also announced that Novartis has suspended Phase 1 development of the first lead product candidate from the outpatient respiratory tract program in favor of developing a second lead compound, which is expected to enter the clinic by the end of the year.

"The identification of a second lead candidate further validates our mechanism-based drug design and demonstrates the speed and efficiency with which this prolific collaboration has brought multiple optimized drug candidates from concept toward the clinic," said Zhengyu Yuan, Ph.D., Senior Vice President of Research. "With the preclinical studies started and an aggressive development timeline established, we expect this candidate to move from preclinical studies into the clinic in a timely manner."

Peptide deformylase inhibitors constitute one of the most promising new antibiotic classes and hold the potential to treat large markets of community bacterial infections. The peptide deformylase inhibitor class of antibiotics targets a novel protein that is essential for bacterial growth and provides the basis for selective activity toward a wide range of bacterial pathogens. This new class has already demonstrated promising in vitro and in vivo activities against a broad spectrum of bacteria, including those resistant to widely used penicillin, cephalosporin, macrolide, and quinolone antibiotics.

Peptide deformylase is a new target for antibacterial drug discovery. Vicuron scientists have combined their expertise in bacterial genomics and mechanism based drug design, with skills in microbiology and pharmacology, in collaboration with expert scientists at Novartis, to identify a family of promising molecules from which a lead compound was chosen which demonstrates selective inhibition of peptide deformylase and exhibits potent broad spectrum activity against key bacterial pathogens both in vitro and in several in vivo models.

- Vicuron Pharmaceuticals Inc.


Subscribe to Antibiotics Newsletter
E-mail Address:


Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients. The company has two New Drug Applications pending with the U.S. Food and Drug Administration for its lead products, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, and anidulafungin, a novel antifungal agent. Vicuron's versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next- generation compounds, many of which are in the later stages of preclinical development. In addition, the company has research collaborations with leading pharmaceutical companies, such as Novartis and Pfizer.

Related Antibiotics News

Two-component lantibiotic with therapeutic potential discovered
Antibiotic inhibits cancer gene activity
Rapamycin shown to inhibit angiogenesis
Tigecycline, world’s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
FDA Warns of Liver Failure With Telithromycin
What is the optimal duration of antibiotic therapy?
Should children with suspected meningitis be given antibiotics before transfer to hospital?
Production Practices Effect Antimicrobial Resistance in Poultry
Aspirin Protects Against Aminoglycoside Induced Hearing Loss
Avelox (Moxifloxacin) is as effective as Levofloxacin combination therapy for severe community-acquired pneumonia

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us